Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[What have we learned from large trials?].

C Lai1, A Cherchi

  • 1Istituto di Cardiologia, Università degli Studi, Cagliari.

Cardiologia (Rome, Italy)
|December 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia.

ESMO open·2026
Same author

Understanding first-line treatment patterns and survival outcomes across sociodemographic groups of women with metastatic triple-negative breast cancer in the United States: a real-world study.

ESMO open·2025
Same author

[Total 3D laparoscopic ileal ureters replacement for bilateral ureters combined with bladder augmentation in the management of post-radiotherapy bilateral ureteral strictures and contracted bladder].

Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences·2025
Same author

Effectiveness of sacituzumab govitecan and management of neutropenia in patients with metastatic triple-negative breast cancer treated in real-world settings in the United States.

ESMO open·2025
Same author

The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study.

ESMO open·2025
Same author

First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab (anti-PD-1), in patients with advanced malignancies.

ESMO open·2025
Same journal

[Prevention in coronary postangioplasty restenosis with omega-3 fatty acids. Results of the Italian study on prevention of restenosis with esapent (ESPRIT)].

Cardiologia (Rome, Italy)·2002
Same journal

[Results of GISSI Prevenzione: diet, drugs, and cardiovascular risk. Researchers of GISSI Prevenzione].

Cardiologia (Rome, Italy)·2002
Same journal

[New therapeutic strategies in heart failure. Which patients need defibrillation backup?].

Cardiologia (Rome, Italy)·2002
Same journal

[Electromechanical re-synchronization with sequential heart stimulation as a new non-pharmacologic treatment of advanced heart failure. Physiopathologic features and clinical results].

Cardiologia (Rome, Italy)·2002
Same journal

[New therapeutic strategies in heart failure. Pharmacologic therapy].

Cardiologia (Rome, Italy)·2002
Same journal

[Genetics as a guide for antihypertensive therapy: future perspectives].

Cardiologia (Rome, Italy)·2002
See all related articles

Thrombolytic therapy is crucial for improving outcomes in myocardial infarction patients. Current research focuses on comparing different thrombolytic drugs and evaluating adjunctive therapies like heparin to minimize side effects and enhance patient care.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Context:

  • Myocardial infarction (MI) management has significantly evolved with the advent of thrombolytic therapy.
  • Clinical trials have established the importance of thrombolysis in restoring coronary patency, improving left ventricular function, and reducing mortality post-MI.

Purpose:

  • To compare the efficacy of different thrombolytic agents such as streptokinase (SK), recombinant tissue plasminogen activator (rt-PA), and anisoylated plasminogen streptokinase activator complex (APSAC).
  • To evaluate the role and efficacy of concomitant therapies, particularly intravenous heparin, in conjunction with thrombolytic treatments.
  • To assess the impact of thrombolytic therapy on key clinical outcomes including recanalization rates, coronary patency, reocclusion incidence, left ventricular function, and patient mortality.

Summary:

Related Experiment Videos

  • Current evidence suggests comparable efficacy among SK, rt-PA, and APSAC.
  • The choice of thrombolytic agent is increasingly influenced by the incidence and profile of side effects rather than differences in efficacy.
  • Intravenous heparin therapy shows promise, supported by theoretical rationale and preliminary clinical trial data, for improving patient outcomes during MI.

Impact:

  • Findings guide clinical decision-making in selecting thrombolytic agents based on safety profiles.
  • Ongoing large-scale clinical trials aim to further refine patient management strategies for acute myocardial infarction.
  • The synergy between large trials and smaller, focused studies is essential for advancing the understanding and treatment of MI.